{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:50Z","timestamp":1792718330132,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018740","name":"Anna-Greta Crafoords Stiftelse f\u00f6r Reumatologisk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018740","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007857","name":"Stiftelsen Konung Gustaf V: s 80-\u00e5rsfond","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005754","name":"Sahlgrenska University Hospital","doi-asserted-by":"publisher","award":["ALFGBG-717761"],"award-info":[{"award-number":["ALFGBG-717761"]}],"id":[{"id":"10.13039\/501100005754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005754","name":"Sahlgrenska University Hospital","doi-asserted-by":"publisher","award":["ALFGBG-965849"],"award-info":[{"award-number":["ALFGBG-965849"]}],"id":[{"id":"10.13039\/501100005754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Patients with RA treated with Janus kinase inhibitors (JAKis) are at increased risk of herpes zoster (HZ). The objective of this study was to investigate the serological immunogenicity and safety of the HZ subunit (HZ\/su) vaccine in RA patients treated with JAKi, for which little is known.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RA patients treated with JAKi (n\u2009=\u200982) at the Department of Rheumatology, Sk\u00e5ne University Hospital, Lund and Malm\u00f6, Sweden, and healthy controls (n\u2009=\u200951) received two doses of the HZ\/su vaccine (Shingrix). Vaccine-specific antibody responses were analysed using indirect ELISA. Post-vaccination antibody levels were compared between patients and controls using analysis of covariance. Potential predictors for vaccine response were investigated using a multivariable linear regression analysis. Self-reported adverse events (AEs) and changes in RA disease activity were analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Following vaccination, vaccine-specific antibody levels increased significantly in both patients and controls (P\u2009&amp;lt;\u20090.0001). A total of 80.5% of patients and 98.0% of controls achieved a \u22654-fold increase in antibody levels. Post-vaccination antibody levels were lower in patients than controls [ratio 0.44 (95% CI 0.31, 0.63)] and lower in patients receiving JAKi\u2009+\u2009methotrexate than JAKi monotherapy [ratio 0.43 (95% CI 0.24, 0.79)]. AEs, mostly mild\/moderate, were common. One patient developed HZ and six patients (6.5%) had increased RA disease activity following vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The HZ\/su vaccine was serologically immunogenic in most RA patients treated with JAKi. Moreover, the vaccine had an acceptable safety profile. These results support recommendations for use of the HZ\/su vaccine in this vulnerable population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov (https:\/\/clinicaltrials.gov), NCT03886038.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead552","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T15:33:26Z","timestamp":1697643206000},"page":"2024-2033","source":"Crossref","is-referenced-by-count":31,"title":["Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3092-5074","authenticated-orcid":false,"given":"Hanna","family":"K\u00e4llmark","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences Lund, Section of Rheumatology, Lund University , Lund, Sweden"},{"name":"Department of Rheumatology, Sk\u00e5ne University Hospital , Lund and Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg , Gothenburg, Sweden"},{"name":"Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-2309","authenticated-orcid":false,"given":"Johanna","family":"Nagel","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Section of Rheumatology, Lund University , Lund, Sweden"},{"name":"Department of Rheumatology, Sk\u00e5ne University Hospital , Lund and Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Gullstrand","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Section of Rheumatology, Lund University , Lund, Sweden"},{"name":"Department of Rheumatology, Sk\u00e5ne University Hospital , Lund and Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon T","family":"Einarsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Section of Rheumatology, Lund University , Lund, Sweden"},{"name":"Department of Rheumatology, Sk\u00e5ne University Hospital , Lund and Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders A","family":"Bengtsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Section of Rheumatology, Lund University , Lund, Sweden"},{"name":"Department of Rheumatology, Sk\u00e5ne University Hospital , Lund and Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meliha C","family":"Kapetanovic","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Section of Rheumatology, Lund University , Lund, Sweden"},{"name":"Department of Rheumatology, Sk\u00e5ne University Hospital , Lund and Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"2024070114082421900_kead552-B1","first-page":"9","article-title":"The nature of Herpes Zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc R Soc Med"},{"key":"2024070114082421900_kead552-B2","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2024070114082421900_kead552-B3","year":"2022"},{"key":"2024070114082421900_kead552-B4","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of Herpes Zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024070114082421900_kead552-B5","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024070114082421900_kead552-B6","doi-asserted-by":"crossref","first-page":"1759720x20936059","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024070114082421900_kead552-B7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024070114082421900_kead552-B8","year":"2022"},{"key":"2024070114082421900_kead552-B9"},{"key":"2024070114082421900_kead552-B10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","article-title":"Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine","volume":"59","author":"Heineman","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"2024070114082421900_kead552-B11","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein e Herpes Zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"2024070114082421900_kead552-B12","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"New Engl J Med"},{"key":"2024070114082421900_kead552-B13","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"New Engl J Med"},{"key":"2024070114082421900_kead552-B14","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1016\/j.vaccine.2020.07.049","article-title":"A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18\u201349 year old patients","volume":"38","author":"Racine","year":"2020","journal-title":"Vaccine"},{"key":"2024070114082421900_kead552-B15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center\u2019s experience with 400 patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2024070114082421900_kead552-B16","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024070114082421900_kead552-B17","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.3390\/ijms24086967","article-title":"Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK Inhibitors: a prospective observational study","volume":"24","author":"Venerito","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024070114082421900_kead552-B18","author":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2017"},{"key":"2024070114082421900_kead552-B19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jviromet.2011.04.014","article-title":"Recombinant glycoprotein E produced in mammalian cells in large-scale as an antigen for varicella-zoster-virus serology","volume":"175","author":"Thomsson","year":"2011","journal-title":"J Virol Methods"},{"key":"2024070114082421900_kead552-B20","author":"R Core Team","year":"2022"},{"key":"2024070114082421900_kead552-B21","author":"Harrell","year":"2022"},{"key":"2024070114082421900_kead552-B22","author":"Wickham","year":"2022"},{"key":"2024070114082421900_kead552-B23","author":"Kassambara","year":"2020"},{"key":"2024070114082421900_kead552-B24","author":"Wickham","year":"2016"},{"key":"2024070114082421900_kead552-B25","author":"Auguie","year":"2017"},{"key":"2024070114082421900_kead552-B26","author":"Wickham","year":"2019"},{"key":"2024070114082421900_kead552-B27","author":"European Medicines Agency. Shingrix: EPAR - Product Information"},{"key":"2024070114082421900_kead552-B28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1080\/21645515.2018.1560918","article-title":"Immune responses to zoster vaccines","volume":"15","author":"Levin","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"2024070114082421900_kead552-B29","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00240-21","article-title":"Comparative antibody responses to the live-attenuated and recombinant Herpes Zoster vaccines","volume":"95","author":"Schmid","year":"2021","journal-title":"J Virol"},{"key":"2024070114082421900_kead552-B30","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024070114082421900_kead552-B31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J Rheumatol"},{"key":"2024070114082421900_kead552-B32","article-title":"Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sj\u00f6gren\u2019s syndrome without disease modifying treatment","author":"Nived","journal-title":"BMC Rheumatol 2018;2:12."}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead552\/52599533\/kead552.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/7\/2024\/58378284\/kead552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/7\/2024\/58378284\/kead552.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T17:58:47Z","timestamp":1719856727000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/7\/2024\/7321123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,10,18]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead552","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2023,10,18]]}}}